Ivarola P, González B, Tedeschini I, Córdoba F, Caraballo R
Hospital de Niños Juan P. Garrahan, Buenos Aires, Argentina.
Rev Neurol. 2024 Feb 16;78(4):93-99. doi: 10.33588/rn.7804.2023260.
To determine clinical, electroencephalographic, therapeutic and evolutive characteristics of a series of oncopediatric patients with acute symptomatic seizures.
We performed a retrospective and prospective descriptive analysis of clinical records of oncopediatric children evaluated by neurology at the comprehensive outpatient Center for Hemato-Oncological Patients during 2017-2021. We included children aged one month to 17 years with intracranial and extracranial tumors who presented with acute symptomatic seizure (ASC). We defined acute symptomatic seizure according to the 2010 International League Against Epilepsy. We classified seizures according to 2017 International League Against Epilepsy classification. We excluded any patient with a diagnosis of previous epilepsy and non-epileptic paroxysmal episodes.
We analyzed 44 cases with a median of 4 years (range: 1 month-17 years) and mean of 5.75 months (range: 1 month-11 months) and 8.33 years (2-17 years). The main etiologies were neurotoxicity and post-surgical context. Four patients presented dysnatremias and two associated with endocranial hypertension. Forty-one electroencephalograms were performed with intercritical results with abnormalities in the baseline rhythm, but without foci or paroxysms. There were no critical recordings. Focal seizures were 25 (56.8%) and generalized seizures 19 (43.18%). Levetiracetam was the most commonly used drug for acute management.
Our cohort shows that ASC, in this population, do not show considerable differences between focal motor and generalized seizures and occur mostly in neurotoxic and post-surgical contexts. Dysnatremias and endocranial hypertension associated with ASC were also recorded. Postcrisis electroencephalograms were without foci or paroxysms and good seizure evolution.
确定一系列患有急性症状性癫痫发作的肿瘤儿科患者的临床、脑电图、治疗及病情演变特征。
我们对2017年至2021年期间在血液肿瘤患者综合门诊中心接受神经科评估的肿瘤儿科患者的临床记录进行了回顾性和前瞻性描述性分析。我们纳入了年龄在1个月至17岁之间、患有颅内和颅外肿瘤且出现急性症状性癫痫发作(ASC)的儿童。我们根据2010年国际抗癫痫联盟的标准定义急性症状性癫痫发作。我们根据2017年国际抗癫痫联盟的分类对癫痫发作进行分类。我们排除了任何先前诊断为癫痫和非癫痫性发作性疾病的患者。
我们分析了44例病例,年龄中位数为4岁(范围:1个月至17岁),平均年龄为5.75个月(范围:1个月至11个月)和8.33岁(2至17岁)。主要病因是神经毒性和术后情况。4例患者出现了电解质紊乱,2例与颅内高压有关。进行了41次脑电图检查,结果为临界值,基线节律异常,但无病灶或痫样放电。没有危急记录。局灶性发作25例(56.8%),全身性发作19例(43.18%)。左乙拉西坦是急性治疗中最常用的药物。
我们的队列研究表明,在该人群中,急性症状性癫痫发作在局灶性运动性发作和全身性发作之间没有显著差异,主要发生在神经毒性和术后情况下。还记录了与急性症状性癫痫发作相关的电解质紊乱和颅内高压。发作后脑电图无病灶或痫样放电,癫痫发作演变良好。